Department of Pathology: Faculty
Uniformed Services University of the Health Sciences
Department of Pathology
4301 Jones Bridge Road, C1094
Bethesda, Maryland 20814-4799
Phone: (301) 295-3450
fax: (301) 295-1640
Philip M. Grimley, M.D.
- B.S. 1956, The City College of New York
- M.D. 1961, Albany Medical College of Union University
Current Research Interests:
Based upon original findings, I am working towards development of new methods for use of low dose drug combinations in cancer chemotherapy based upon a principle of retardation of the cell cycle progression during S or G2 phases. We have defined a category of "retardation agents" which can be combined with several protein kinase inhibitors to accelerate and potentiate malignant cell killing. Present efforts are focused upon combinations using platinum-coordination compounds which are first line agents in the treatment of ovarian epithelial cancers, germ cell cancers and lung cancers. In auxiliary studies we are analyzing population based statistics for ovarian cancer to learn more about possible differences in the pathogenesis of morphologic subtypes and differences in therapeutic response.
Kirken RA, Marabarba M.G., Xu J, Liu X., Farrar WL, Henninghausen L, Larner AC, Grimley, PM, Rui,H. Prolactin stimulates serine/tyrosine phosphorylation and complex formation of multiple Stat5 variants in Nb2 lymphocytes. J. Biol. Chem. 272:15459-65, 1997.
Grimley PM, Mehta S. United States patent application: Method of dynamic retardation of cell cycle kinetics to potentiate cell damage. Serial No. 08/667,543 Filed June 1996.
Carbone M, Rizzo P, Grimley PM, Procopio A, Mew DJY, Shridhar V, De Bartolomeis A, Esposito V, Guiliano MT, Steinberg SM, Levine AS, Giordano A, Pass HI. Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nature Medicine 3:908-912, 1997.
Petricoin EF III, Ito S, Williams BL, Audet S, Stancato LF, Gamero A, Clouse K, Grimley P, Weiss A, Beeler J, Finbloom DS, Shores E, Abraham R and Larner AC. Antiproliferative actions of IFN alpha require components necessary of T cell receptor signaling. Nature 390: 629-631, 1997.
Rui H, Xu J, Mehta S, Fang H, Williams J, Dong F, Grimley PM. Activation of the Jak2-Stat5 signaling pathway in Nb2 lymphoma cells by an anti-apoptotic agent, aurintricarboxylic acid. J. Biol.Chem 273,28-32, 1998.
Grimley PM, Fang H, Rui H, Petricoin EF III, Ray S, Dong F, Fields KH, Hu R, Zoon KC, Audet S, Beeler J. Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-alpha. Blood 91:3017-3027, 1998.
Schaber JD, Fang H, Xu, Jun, Grimley PM, Rui H. Prolactin activates Stat1 but does not antagonized Stat1-mediated growth inhibition by Type I interferons in human breast cancer cells. Cancer Res., 58:1914-9, 1998.
Dong F, Liu X, deKoning JP, Touw IP, Henninghausen L, Larner A and Grimley PM. Stimulation of Stat5 by granulocyte colony-stimulating factor (G-CSF) is modulated by two distinct cytoplasmic regions of the G-CSF receptor. J Immunol 161:6503-6509, 1998.
Nevalainen MT., Ahonen TJ, Yamashita H, Chandrashekar V, Bartke A, Grimley PM, Robinson GW, Hennighausen L and Rui H. Epithelial Defect in Prostates of Stat5a-Null Mice. Laboratory Investigation 80(7):993, 2000.
Albright CD, Grimley PM, Jones RT and Resau JH. Differential Effects of TPA and Retinoic Acid on Cell-Cell Communication in Human Bronchial Epithelial Cells. Experimental and Molecular Pathology 72:62-67, 2002.
Marchisio M, Grimley PM, DiBaldassarre A, Santa Venere E and Miscia S. Novel Shift of JAK/Stat Signalling Characterizes The Protective Effect of Aurintricarboxylic Acid (ATA) From Tumor Necrosis Factor- α Toxicity In Human B Lymphocytes. International Journal of Immunopathology and Pharmacology 17(1):5-14, 2004.
DiPietro R, Fang H, Fields K, Miller S, Flora M, Petricoin EC, Dveksler G, Ranna RA and Grimley PM. Peroxiredoxin Genes Are Not Induced In Myeloid Leukemia Cells Exposed To Ionizing Radiation. International Journal of Immunopathology and Pharmacology 19(3):517-425, 2006.